Merck's Terns Acquisition Intensifies Oncology Bet Amid Looming Keytruda Cliff

What happened

Merck has acquired Terns Pharmaceuticals, a move touted to bolster its cancer pipeline and reinforce its role as a serial acquirer. This comes as the company navigates a critical 'bridge year' in 2026, with loss-of-exclusivity events for Januvia/Janumet and Bridion threatening earnings while Keytruda—comprising 49% of 2025 sales—faces a biosimilar risk window starting December 2028. The acquisition is framed as a strategic effort to secure new growth engines and diversify beyond Keytruda dependency, aligning with management's aggressive M&A strategy to offset upcoming revenue gaps. However, investors should look past the optimistic spin, as this deal likely involves substantial acquisition charges, similar to the ~$5.8B reported for Terns and ~$9.0B for Cidara, which could compress GAAP earnings and anchor the stock to a lower multiple. Ultimately, this reinforces Merck's high-stakes gamble to build a post-Keytruda future, but it does little to alleviate near-term execution risks or the core concentration overhang.

Implication

Investors face heightened earnings volatility as acquisition charges, like the ~$5.8B for Terns, could pressure GAAP results and limit multiple expansion despite strategic rationale. The deal supports Merck's pipeline diversification but underscores reliance on M&A to fill the post-Keytruda void, with integration and clinical success now critical to justifying the premium paid. Near-term, focus intensifies on whether Merck can meet its FY2026 sales guidance of $65.5B–$67.0B amidst LOE headwinds, as any miss would erode bridge-year credibility and trigger downside scenarios. Additionally, the accumulation of large charges risks creating a narrative of 'earnings noise' that distracts from operational progress, potentially delaying investor confidence. Therefore, while the acquisition aligns with long-term strategy, it reinforces the need for cautious monitoring of charge impacts and 1H26 execution before considering a position change.

Thesis delta

The acquisition does not shift the core 'WAIT' thesis but sharpens the focus on acquisition-related risks and execution pressure. It highlights that Merck's bridge to post-Keytruda growth is increasingly reliant on costly M&A, raising stakes for charge management and pipeline delivery without altering the fundamental uncertainty around 2026 outcomes.